Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-center clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial...
Mursla BioNov 25 2024 Mursla Bio, a leader in Extracellular Vesicle science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-center clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial College London, University Hospital of Santa Maria and the Medical University of Graz.
The results are part of MEV01 and based on 464 patient samples, primarily collected prospectively, within a western population, representing etiologies such as MASH / fatty liver disease, alcoholic liver disease and hepatitis. Mursla Bio developed the EvoLiver test by isolating organ-specific hepatocyte extracellular vesicles from blood samples, enabling the validation of a novel HCC biomarker signature comprised of fewer than 10 h-EV microRNAs and proteins.
EvoLiver leverages a pioneering platform that isolates h-EVs, identifies and validates novel multiomics biomarkers to distinguish HCC with cirrhosis from non-cancerous cirrhosis. EvoLiver’s low blood volume requirement and quick turnaround times support improved patient outcomes while streamlining disease management for clinicians and patients.
Liver Liver Cancer Biomarker Biopsy Blood Blood Test Carcinoma Cirrhosis Hepatocellular Carcinoma Hospital Liver Disease Multiomics Technology Ultrasound
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mursla Bio joins leading European consortium to advance clinical applications based on extracellular vesicle scienceMursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, announced it has been invited to join EVEREST, a leading European consortium.
Read more »
Barcoding small extracellular vesicles with new CRISPR-based systemCell-to-cell communication through nanosized particles, working as messengers and carriers, can now be analyzed in a whole new way, thanks to a new method involving CRISPR gene-editing technology.
Read more »
New imaging tool analyzes extracellular vesicles to track cancer progressionA University of Rochester research team is reporting a new way to detect cancer cells with a 'liquid biopsy' that's designed to be simpler, faster, and more informational than current methods.
Read more »
UCD leads major EU project on extracellular vesicles for biomedical researchA major EU project coordinated from UCD is set to push the frontiers of biomedical research by exploring the transformative potential of extracellular vesicles (EVs).
Read more »
CN Bio launches PhysioMimix Bioavailability assay kit: Human 18CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18.
Read more »
Bio, News, High-Res Photos & High Quality VideosFind everything in one place on Esteban Ocon including their biography, latest news and updates, high resolution photos, high quality videos and expert analysis
Read more »